New Medicines in Development
Today, over 3,200 new medicines are in development. Many of these potential new medicines will fail in clinical trials, but some may represent tomorrow's new treatments. In total, it takes approximately 10 to 15 years to go through the drug discovery and clinical development process and bring a medicine to the market. The process is also costly—the average R&D investment for each new medicine is $1.2 billion, including the cost of failures.[i]
Alzheimer's Disease
There are currently 93 medicines in development by America's biopharmaceutical companies to treat Alzheimer's disease and other dementias. Read more
Arthritis
The are 198 medicines currently in development to help the more than 50 million Americans afflicted with at least one of the 100 different musculoskeletal disorders.
Read more
Asthma
America's biopharmaceutical research companies are developing 74 medicines to treat asthma, which affects more than 24 million American adults and children. Read more
Biologic Medicines
America’s biopharmaceutical research companies are testing a record 907 new medicines and vaccines that are derived through biotechnology. Read more
Cancer
There are 981 medicines and vaccines in development to treat patients with cancer. These treatments include 121 for lung cancer and 119 for breast cancer. Read more
Children
America’s pharmaceutical research and biotechnology companies are developing 282 medicines for the special health care needs of children. Read more
Chronic Diseases Affecting Older Americans
There are currently 465 medicines in development by America's biopharmaceutical companies to target the 10 leading chronic conditions affecting older Americans. Read more
Chronic Obstructive Pulmonary Disease (COPD)
There are currently more than 50 medicines in development for COPD, a disease that affects more than 13 million American adults and remains the third leading cause of death in the United States. Read more
Diabetes
There are currently 221 medicines in development by America's biopharmaceutical companies to treat diabetes. Read more
Heart Disease and Stroke
Nearly 300 potential medicines to treat heart disease and stroke are in the research pipeline. Read more
HIV/AIDS
Pharmaceutical researchers are testing nearly 75 medicines and vaccines to treat or prevent HIV/AIDS. Read more
Infectious Diseases
America’s biopharmaceutical research companies have 395 new medicines and vaccines in the pipeline to fight infectious diseases — all in later stages of development. Read more
Leukemia and Lymphoma
Each year nearly 150,000 Americans are diagnosed with a blood cancer—accounting for about 9 percent of all new cancer diagnoses. With 241 medicines in development by America's biopharmaceutical companies to target leukemia, lymphoma, myeloma and other cancers of the blood, there is great hope for patients diagnosed with these diseases. Read more
Mental Illnesses
There are 187 innovative medicines in development to treat patients with mental illnesses. These treatments include 52 for depression, 37 for schizophrenia and 26 for anxiety disorders. Read more
Rare Diseases
There are 460 medicines currently in development to treat or prevent hundreds of rare diseases. Read more
Skin Diseases
There are currently 277 medicines in development to help the more than 100 million Americans, one third of the U.S. population, that suffer from at least one skin disease. Read more
Vaccines
America's biopharmaceutical research companies are currently developing nearly 300 vaccines for the prevention and treatment of a wide variety of diseases. Read more
Women
Currently, there are 851 medicines in development for diseases that disproportionately or only affect women. Read more
[i] J.A. DiMasi and H.G. Grabowski, “The Cost of Biopharmaceutical R&D: Is Biotech Different?” Managerial and Decision Economics 28 (2007): 469–479.
.gif)